Results 181 to 190 of about 170,148 (277)

Firearm businesses as partners in suicide prevention: a cross-sectional study of the Gun Shop Project in Colorado, USA. [PDF]

Inj Prev
Wright-Kelly E, Buck-Atkinson JT, Betz ME, Little K, Little JS, Kingston BE, Sigel E, Arredondo-Mattson S.   +7 more
europepmc   +1 more source

Assisted Suicide: The Moral Equation [PDF]

, 1993
Doerflinger, Richard M.
core   +1 more source

Huntington's Disease and Huntington's Disease‐like 2 (HDL2) in Martinique

Movement Disorders Clinical Practice, EarlyView.
ABSTRACT Background Huntington's Disease‐like 2 (HDL2), caused by a CAG repeat expansion in JPH3, closely resembles HD. All reported HDL2 patients to date have some African ancestry. While both disorders exist in the Caribbean, their relative frequency and clinical characteristics remain largely unknown.
Ignacio Antolin‐Sanfeliz, Anna‐Gaelle Giguet‐Valard, Sophie Duclos, Cécile Cazeneuve, Chloé Angelini, Aïssatou Signaté, Russell L. Margolis, Cyril Goizet, Rémi Bellance   +8 more
wiley   +1 more source

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma, Panagiota Tsitsi, Nirosen Vijiaratnam, Camila Aquino, Stephen R. Duma, Norbert Kovacs, Kigocha Lameck Okeng'o, Aparna Wagle Shukla, Roongroj Bhidayasiri, Tiago A. Mestre, Alvaro Sanchez Ferro, Alberto J. Espay, Michelle H.S. Tosin, Matej Skorvanek, Ioanna Markaki   +14 more
wiley   +1 more source

Documented End‐of‐Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease and atypical parkinsonism are characterized by motor and non‐motor symptoms. As the disease advances, planning for end‐of‐life (EoL) care becomes increasingly important. However, consensus‐based European guidelines for advance care planning and documentation of EoL care preferences for parkinsonism are lacking ...
Bauke W. Dijkstra, Catharina Muente, Michela Garon, Kristina Rosqvist, Monica Scharfenort, Katharina M. Lex, Philip Poku, Eirini Nixina, Pille Taba, Ülle Krikmann, Katrin Sikk, Katie Flanagan, Anette E. Schrag, Spyros Konitsiotis, Miltiadis Makrydimas, Stefan Lorenzl, Per Odin, David J. Pedrosa, Kris C.P. Vissers, Marieke M. Groot, Bastiaan R. Bloem, Marjan J. Meinders, Angelo Antonini, the PD_Pal consortium, Argyri Tsakanika, Dhaval Trivedi, Dimitri Gatsios, Dimitrios Fotiadis, K. Ray Chaudhuri, Nikolaos Moschos, Piret Paal   +30 more
wiley   +1 more source

The Role of the Physician in Caring for Patients Pursuing VSED: Challenging the Conventional Approach. [PDF]

J Am Geriatr Soc
Frush BW, Curlin FA, Sulmasy DP.
europepmc   +1 more source

Underlying Mechanisms of the Treatment Efficacy of (R, S)‐Ketamine for Post‐Traumatic Stress Disorder and Depression: A Review

Medicine Advances, EarlyView.
Research shows that (R, S)‐ketamine and its stereoisomers effectively reduce symptoms of post‐traumatic stress disorder (PTSD) and treatment‐resistant depression, with (R)‐ketamine offering similar benefits with fewer side effects. Evidence highlights specific neural circuits and regions, including the dentate gyrus, prefrontal cortex, vCA3, dorsal ...
Thomas Edward Cutting, Richard Evans Hartman   +1 more
wiley   +1 more source

Experience reports from active volunteer members in German right-to-die organisations through qualitative content analysis. [PDF]

BMC Med Ethics
Ohm S, Bozzaro C.
europepmc   +1 more source

Phase 3b Extension Study MT‐1186‐A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims An On/Off dosing regimen of intravenous (IV) edaravone and edaravone oral suspension is currently approved in the US for treatment of amyotrophic lateral sclerosis (ALS). Placebo‐controlled clinical trials showed that IV edaravone slows physical functional decline.
Angela Genge, Jeffrey Rothstein, Shari De Silva, Lorne Zinman, Marvin Chum, Adriano Chiò, Gen Sobue, Masashi Aoki, Hiide Yoshino, Manabu Doyu, Daniel Selness, Vesna Todorovic, Manabu Hirai, Nissim Sasson, Fumihiro Takahashi, Michelle Cecić, Art Wamil, Stephen Apple   +17 more
wiley   +1 more source

Assessment of Discriminant Validity for Measures of Hope and Hopelessness in Adults With an Acute Cardiac Event

Research in Nursing &Health, EarlyView.
ABSTRACT Hope and hopelessness are sometimes considered to be two ends of a spectrum. Hope is associated with positive health outcomes in healthy and ill populations. Conversely, hopelessness has been associated with increased adverse clinical events and death in patients with ischemic heart disease (IHD).
Holli A. DeVon, Nathan Tintle, Eleanor Rivera, Anna Davis, Susan L. Dunn   +4 more
wiley   +1 more source